Gastroenterology
Collagenous Colitis
4
Pipeline Programs↗
0
Active Trials↗
3
Companies Involved↗
Collagenous Colitis is an early-stage landscape with 4 programs across 3 companies. The most active players are Salix, Ferring, Takeda. 1 therapy is approved with 3 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Approved1
Analysis
Trial Status
5
clinical trials
Completed3 · 60%
Unknown status2 · 40%
Clinical Trials
Trial Activity
Rifaximin-treatment of Collagenous Colitis
Unknown status·—·Phase 3·NCT03658993·50 enrolled
Budesonide Capsules vs. Mesalazine Granules vs. Placebo in Collagenous Colitis
Completed·—·Phase 3·NCT00450086·92 enrolled
SOIBD Collagenous Colitis Maintenance Study
Completed·—·Phase 3·NCT01278082·92 enrolled
Long-Term Treatment of Collagenous Colitis With Budesonide
Unknown status·—·Phase 3·NCT00139165·36 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)